NCT04689828 2026-03-23
PSMAfore
Novartis
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT03042468 2025-09-17
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT03805594 2025-02-25
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Completed
NCT03511664 2025-01-13
VISION
Endocyte
Phase 3 Completed
NCT03545165 2021-08-24
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT03042312 2021-03-24
RESIST-PC
Endocyte
Phase 2 Terminated